Q&A: Novo Nordisk Foundation’s Cellerator CEO Thomas Carlsen digs into $135.4M Danish cell therapy facility
The Novo Nordisk Foundation revealed Thursday it has committed €127 million ($135.4 million) to build a new cell therapy facility in Denmark, which is set to be completed by 2027.
The facility, Cellerator, will be located at the Technical University of Denmark in Lyngby, and will facilitate collaboration between public and private companies — including academia, biotech and pharma companies.
The site will focus on the final development and upscaling of cell therapies for diseases such as chronic heart failure, Parkinson’s disease, type 1 diabetes and cancer for use in clinical trials. It will support therapies derived from embryonic stem cells, induced pluripotent stem cells and adult stem cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.